Mangalam Drugs and Organics is expanding its anti-malaria API portfolio with the introduction of Pyronaridine, having recently received prestigious pre-qualification from WHO Geneva. The World Health Organization (WHO) has endorsed the Pyronaridine and Artesunate combination for malaria treatment. It is the second company, following the innovator, to achieve this significant milestone.
This development will position the company at the forefront of anti-malaria API production globally and is expected to drive substantial growth and profitability for the Company. In this regard, the company is currently collaborating with the Bill and Melinda Gates Foundation (BMGF) for technical assistance to achieve backward integration of Pyronaridine, which will enhance the cost-competitiveness of this API in the coming years.
The Medicine for Malaria Venture (MMV), headquartered in Geneva, Switzerland, is a non-profit organization dedicated to the development and support of innovative antimalarial therapies. MMV is actively engaged in advancing new treatments for malaria and is focused on optimizing combination therapies. The organization has endorsed the use of the pyronaridine-artesunate combination therapy as a recommended treatment for malaria. This combination leverages the synergistic effects of both drugs to enhance therapeutic efficacy and combat malaria more effectively.
Mangalam Drugs and Organics is an India-based company engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |